Moderna shares surge 30% after reporting 'positive' data on early-stage coronavirus vaccine trial

Moderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, sending the company's shares surging by about 30% in premarket trading.

from Health and Science https://ift.tt/2TiTtCW
https://ift.tt/eA8V8J
https://ift.tt/2zIUzyH